To date, several SLC inhibitors have been granted approval for clinical use, although they target a small fraction of the potentially druggable SLC family and mainly consist of neurotransmitter reuptake inhibitors for neuropsychiatric disorders, diuretics to control blood pressure, and glucose transport inhibitors to treat diabetes (30, 45). Here, CCL21 is linked to diabetes mellitus.